Health Technology Reviews
Published February 11, 2022
- Evidence from 1 retrospective cohort study (identified in 1 systematic review) suggested that anakinra may reduce 28-day mortality and the risk for death in adults diagnosed with hemophagocytic lymphohistiocytosis (HLH).
- Due to the very low certainty of evidence from the single cohort study included in the systematic review, there is insufficient information to draw reliable conclusions regarding the clinical effectiveness of anakinra compared to standard treatments for patients diagnosed with HLH.
- No evidence on the safety or cost-effectiveness of anakinra compared to current standard treatments or to placebo was identified.